Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Udo Holtick

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|December 13, 2023
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell TransplantationMax Bittrich, Katharina Kriegsmann, Carola Tietze-Stolley, et al.
Cell|February 1, 2020
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing AntibodyPhilipp Schommers, Henning Gruell, Morgan E Abernathy, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 30, 2023
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB StudyKatharina Kriegsmann, Max Bittrich, Sandra Sauer, et al.
Blood|March 22, 2022
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in GermanyWolfgang A Bethge, Peter Martus, Michael Schmitt, et al.
Blood Advances|October 22, 2025
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell EngagersGiulia Magno, Kai Rejeski, Giulia Rappa, et al.
Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.
Nature Medicine|April 17, 2023
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trialZachary D Crees, Michael P Rettig, Reyka G Jayasinghe, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Blood Advances|April 16, 2025
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphomaEvgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|December 13, 2023
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell TransplantationMax Bittrich, Katharina Kriegsmann, Carola Tietze-Stolley, et al.
Cell|February 1, 2020
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing AntibodyPhilipp Schommers, Henning Gruell, Morgan E Abernathy, et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 30, 2023
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB StudyKatharina Kriegsmann, Max Bittrich, Sandra Sauer, et al.
Blood|March 22, 2022
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in GermanyWolfgang A Bethge, Peter Martus, Michael Schmitt, et al.
Blood Advances|October 22, 2025
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell EngagersGiulia Magno, Kai Rejeski, Giulia Rappa, et al.
Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.
Nature Medicine|April 17, 2023
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trialZachary D Crees, Michael P Rettig, Reyka G Jayasinghe, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Blood Advances|April 16, 2025
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphomaEvgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Pageof 10